Abstract
Zika virus (ZIKV) infection and its associated congenital and other neurological disorders, particularly microcephaly and other fetal developmental abnormalities, constitute a World Health Organization (WHO) Zika Virus Research Agenda within the WHO’s R&D Blueprint for Action to Prevent Epidemics, and continue to be a Public Health Emergency of International Concern (PHEIC) today. ZIKV pathogenicity is initiated by viral infection and propagation across multiple placental and fetal tissue barriers, and is critically strengthened by subverting host immunity. ZIKV immune evasion involves viral non-structural proteins, genomic and non-coding RNA and microRNA (miRNA) to modulate interferon (IFN) signaling and production, interfering with intracellular signal pathways and autophagy, and promoting cellular environment changes together with secretion of cellular components to escape innate and adaptive immunity and further infect privileged immune organs/tissues such as the placenta and eyes. This review includes a description of recent advances in the understanding of the mechanisms underlying ZIKV immune modulation and evasion that strongly condition viral pathogenesis, which would certainly contribute to the development of anti-ZIKV strategies, drugs, and vaccines.
Highlights
Between 2011 and 2018, World Health Organization (WHO) identified, alerted and tracked more than 1400 epidemic events in 172 countries due to emerging viruses, such as influenza, Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Ebola, Yellow Fever, Zika, and others [1]
This study discovered an interesting observation relating the distinct specificity for Zika virus (ZIKV) proteins and epitopes shown by protective CD8+ T cells generated in ZIKV infected individuals that have previously experienced a DENV infection compared with individuals without any previous reported DENV infection
Multiple NS proteins of ZIKV negatively modulate the antiviral response at various levels by inhibiting type I IFN production and the expression of downstream IFN-stimulated genes (ISGs), acting on the IFN-associated cyclic GMP-AMP synthase (cGAS)-stimulator of IFN genes (STING) pathway, targeting with TANK-binding kinase 1 (TBK1) and impairing IRF3 promoters, or modulating RIG-I- and melanoma differentiation-associated gene 5 (MDA5)-directed type I IFN induction, as well as different steps of the antiviral type I IFN system against RNA viruses such as ZIKV
Summary
Between 2011 and 2018, World Health Organization (WHO) identified, alerted and tracked more than 1400 epidemic events in 172 countries due to emerging viruses, such as influenza, Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Ebola, Yellow Fever, Zika, and others [1]. These epidemic diseases are a prelude of the new global era the world is facing, and hallmark of high-impact, fast-spreading outbreaks that are increasingly difficult to manage, as is occurring nowadays with the new worldwide infection by the emerged SARS Coronavirus 2 (SARS-CoV-2) responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic [2]. The present article aims to review the mechanisms of ZIKV immune evasion related to viral non-structural (NS) proteins, genomic and non-coding viral RNA, as well as microRNA (miRNA) generated during ZIKV infection to modulate cellular environment, in order to escape immunity and cause ZIKV complex pathology
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have